Structure:~Prospective, single center, randomized, double-masked, parallel treatment comparison study. Subjects will be randomized to one of the following treatment arms to be dosed bilaterally twice daily (BID) for the first dosing period and four times daily (QID) for the second dosing period:~Prednisolone Acetate 1% ophthalmic suspension~Prednisolone Acetate 0.12% ophthalmic suspension~Loteprednol Etabonate 0.2% ophthalmic suspension~Tears Naturale® II~Duration:~Approximately four (4) weeks~Controls:~Artificial Tears (Tears Naturale® II)
To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (Tears Naturale® II) in the prevention of the signs and symptoms of allergic conjunctivitis. Comparisons will be made following 1 week of twice daily (BID) dosing and 1 week of four times daily (QID) dosing.